Epidemiology and clinical pattern of psoriatic arthritis in Germany: A prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis

British Journal of Dermatology

Volumn 160, Issue 5, 2009, Pages 1040-1047

  Reich, K ^a   Kruger K ^b   Mossner R ^c   Augustin, M ^d  

^a DERMATOLOGIKUM HAMBURG   (Germany)

^b Rheumatological Practice   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Epidemiology; Health care; Psoriasis; Psoriatic arthritis

Indexed keywords

ANTIPSORIASIS AGENT;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; COMPARATIVE STUDY; CONCURRENT INFECTION; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; GERMANY; HEALTH CARE; HEALTH CENTER; HUMAN; INTERPHALANGEAL JOINT; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; OBSERVATIONAL STUDY; PHOTOTHERAPY; POLYARTHRITIS; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; SKIN MANIFESTATION;

ARTHRITIS, PSORIATIC; CROSS-SECTIONAL STUDIES; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 64849094127     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.09023.x     Document Type: Article

References (45)

1. Boehncke WH, Friedrich M, Kaltwasser JP et al. Psoriatic arthritis - an interdisciplinary challenge. Dtsch Arztebl 2006 103 : A1455 61.
2. Gladman DD, Antoni C, Mease PJ et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005 64 : ii14 17.
3. Gladman DD, Mease PJ, Healy P et al. Outcome measures in psoriatic arthritis. J Rheumatol 2007 34 : 1159 66.
4. Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 2006 54 : 685 704.
5. Myers WA, Gottlieb AB, Mease P. Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin Dermatol 2006 24 : 438 47.
6. Reich K, Sinclair R, Roberts G et al. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis. Curr Med Res Opin 2008 24 : 1237 54.
7. Kavanaugh A, Ritchlin C, Boehncke WH. Quality indicators in psoriatic arthritis. Clin Exp Rheumatol 2007 25 (Suppl. 47 98 101.
8. Qureshi AA, Husni ME, Mody E. Psoriatic arthritis and psoriasis: need for a multidisciplinary approach. Semin Cutan Med Surg 2005 24 : 46 51.
9. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973 3 : 55 78.
10. Jones SM, Armas JB, Cohen MG et al. Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol 1994 33 : 834 9.
11. Marsal S, Armadans-Gil L, Martinez M et al. Clinical, radiographic and HLA associations as markers for different patterns of psoriatic arthritis. Rheumatology (Oxford) 1999 38 : 332 7.
12. Brockbank JE, Stein M, Schentag CT, Gladman DD. Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis 2005 64 : 188 90.
13. Rothschild BM, Pingitore C, Eaton M. Dactylitis: implications for clinical practice. Semin Arthritis Rheum 1998 28 : 41 7.
14. Fredriksson T, Pettersson U. Severe psoriasis - oral treatment with a new retinoid. Dermatologica 1978 157 : 238 44.
15. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994 19 : 210 16.
16. Hongbo Y, Thomas CL, Harrison MA et al. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol 2005 125 : 659 64.
17. Reich K, Mössner R, König IR et al. Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1beta are associated with different subtypes of psoriasis characterized by early and late disease onset. J Invest Dermatol 2002 118 : 155 63.
18. Reich K, Huffmeier U, König IR et al. TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk allele. Arthritis Rheum 2007 56 : 2056 64.
19. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol 2005 152 : 861 7.
20. Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005 153 : 486 97.
21. Love TJ, Gudbjornsson B, Gudjonsson JE, Valdimarsson H. Psoriatic arthritis in Reykjavik, Iceland: prevalence, demographics, and disease course. J Rheumatol 2007 34 : 2082 8.
22. Veale D, Rogers S, Fitzgerald O. Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol 1994 33 : 133 8.
23. Salvarani C, Lo Scocco G, Macchioni P et al. Prevalence of psoriatic arthritis in Italian psoriatic patients. J Rheumatol 1995 22 : 1499 503.
24. Gelfand JM, Gladman DD, Mease PJ et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005 53 : 573.
25. Pedersen OB, Svendsen AJ, Ejstrup L et al. The occurrence of psoriatic arthritis in Denmark. Ann Rheum Dis 2008 67 : 1422 6.
26. Alenius GM, Stenberg B, Stenlund H et al. Inflammatory joint manifestations are prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic patients, and evaluation of a psoriatic and arthritic questionnaire. J Rheumatol 2002 29 : 2577 82.
27. Zachariae H, Zachariae R, Blomqvist K et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol (Stockh) 2002 82 : 108 13.
28. Gisondi P, Girolomoni G, Sampogna F et al. Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. Eur J Dermatol 2005 15 : 279 83.
29. Gottlieb AB, Mease PJ, Mark Jackson J et al. Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices. J Dermatolog Treat 2006 17 : 279 87.
30. Madland TM, Apalset EM, Johannessen AE et al. Prevalence, disease manifestations, and treatment of psoriatic arthritis in Western Norway. J Rheumatol 2005 32 : 1918 22.
31. Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM et al. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol 1991 30 : 245 50.
32. Scarpa R, Soscia E, Peluso R et al. Nail and distal interphalangeal joint in psoriatic arthritis. J Rheumatol 2006 33 : 1315 19.
33. Taylor W, Gladman D, Helliwell P et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006 54 : 2665 73.
34. Helliwell PS, Porter G, Taylor WJ The CASPAR Study Group. Polyarticular psoriatic arthritis is more like oligoarticular psoriatic arthritis, than rheumatoid arthritis. Ann Rheum Dis 2007 66 : 113 17.
35. Traupe H, Robra BP. Schuppenflechte. Gesundheitsberichterstattung des Bundes, Heft 11. Berlin : Robert Koch-Institut, Statistisches Bundesamt, 2002.
36. Zink A, Thiele K, Huscher D et al. Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2006 33 : 86 90.
37. Frankel EH, Strober BE, Crowley JJ et al. Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE. Cutis 2007 79 : 322 6.
38. Gladman DD, Mease PJ, Cifaldi MA et al. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann Rheum Dis 2007 66 : 163 8.
39. Kavanaugh A, Antoni CE, Gladman D et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006 65 : 1038 43.
40. Reich K, Nestle FO, Papp K et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol 2006 154 : 1161 8.
41. Revicki D, Willian MK, Saurat JH et al. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 2008 158 : 549 57.
42. Alenius GM. Psoriatic arthritis - new insights give new options for treatment. Curr Med Chem 2007 14 : 359 66.
43. Mease PJ. Current treatment for psoriatic arthritis and other spondyloarthritides. Rheum Dis Clin North Am 2006 32 (Suppl. 1 11 20.
44. Turkiewicz AM, Moreland LW. Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options. Arthritis Rheum 2007 56 : 1051 66.
45. Wellborne F. New directions in the standard of care for inflammatory arthritis. Postgrad Med 2006 Spec No : 24 31.